Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present a pre-recorded corporate presentation at the H.C. Wainwright 24th Annual Global Investment Conference. The presentation will be accessible on September 12, 2022, at 7:00 a.m. ET. An audio webcast of the presentation will also be available on Chimerix's Investor Relations website for about 90 days. Chimerix is dedicated to developing treatments that enhance the lives of patients with severe diseases, with its leading program, ONC201, focused on H3 K27M-mutant glioma.

DURHAM, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a pre-recorded corporate presentation at the H.C. Wainwright 24th Annual Global Investment Conference made available on Monday, September 12, 2022 at 7:00 a.m. ET.

An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

CONTACT:
Investor Relations:        
Michelle LaSpaluto
919 972-7115
ir@chimerix.com

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

 

FAQ

When will Chimerix's corporate presentation take place?

Chimerix's corporate presentation will occur on September 12, 2022, at 7:00 a.m. ET.

Where can I find the audio webcast of Chimerix's presentation?

The audio webcast of Chimerix's presentation will be available on their Investor Relations website.

What is Chimerix's primary clinical-stage development program?

Chimerix's most advanced clinical-stage development program is ONC201, aimed at treating H3 K27M-mutant glioma.

How long will the audio webcast of the presentation be available?

The audio webcast will be archived for approximately 90 days.

Who is presenting at the H.C. Wainwright 24th Annual Global Investment Conference?

Mike Sherman, the CEO of Chimerix, will be presenting.